HYPOTHESIS: To define the role of surgical staging in limited (T1-2, N0-1) oropharyngeal squamous cell cancers. STUDY DESIGN: Retrospective. METHODS: Forty-nine limited oropharyngeal squamous cell cancers of the tonsil, tongue base, or posterior pharyngeal wall-treated surgically were identified. RESULTS: Thirty-five percent were cT1 and 65% were cT2 tumors although 58% were cN0 and 42% were cN1. Forty-six patients underwent neck dissections. Surgical staging altered T-stage in 26% (13/49), nodal status in 23% (11/46), and clinical staging in 40% (20/49) of patients. Among 35 disease-free patients, 28% (4/20) of stage I/II patients received postoperative radiation and chemotherapy was avoided in 80% (12/15) of stage III patients. T1 tumors seemed to have better outcomes (P = .06). The 3 year disease-free survival and 5 year overall survival was 85% and 83%, respectively. CONCLUSIONS: Surgical staging identifies patients in whom intensification of treatment with chemotherapy can be most appropriately applied, and enables de-intensification of therapy in pathology confirmed stage I/II disease.
HYPOTHESIS: To define the role of surgical staging in limited (T1-2, N0-1) oropharyngeal squamous cell cancers. STUDY DESIGN: Retrospective. METHODS: Forty-nine limited oropharyngeal squamous cell cancers of the tonsil, tongue base, or posterior pharyngeal wall-treated surgically were identified. RESULTS: Thirty-five percent were cT1 and 65% were cT2tumors although 58% were cN0 and 42% were cN1. Forty-six patients underwent neck dissections. Surgical staging altered T-stage in 26% (13/49), nodal status in 23% (11/46), and clinical staging in 40% (20/49) of patients. Among 35 disease-free patients, 28% (4/20) of stage I/II patients received postoperative radiation and chemotherapy was avoided in 80% (12/15) of stage III patients. T1 tumors seemed to have better outcomes (P = .06). The 3 year disease-free survival and 5 year overall survival was 85% and 83%, respectively. CONCLUSIONS: Surgical staging identifies patients in whom intensification of treatment with chemotherapy can be most appropriately applied, and enables de-intensification of therapy in pathology confirmed stage I/II disease.
Authors: Dana M Hartl; Alfio Ferlito; Carl E Silver; Robert P Takes; Sandro J Stoeckli; Carlos Suárez; Juan P Rodrigo; Andreas M Sesterhenn; Carl H Snyderman; David J Terris; Eric M Genden; Alessandra Rinaldo Journal: Eur Arch Otorhinolaryngol Date: 2011-05-12 Impact factor: 2.503
Authors: Kara S Davis; Chwee Ming Lim; David A Clump; Dwight E Heron; James P Ohr; Seungwon Kim; Umamaheswar Duvvuri; Jonas T Johnson; Robert L Ferris Journal: Head Neck Date: 2015-12-17 Impact factor: 3.147
Authors: Marcie Tauzin; Amy Rabalais; Joseph L Hagan; Charles G Wood; Robert L Ferris; Rohan R Walvekar Journal: World J Surg Oncol Date: 2010-08-16 Impact factor: 2.754